In this White Paper, Pete sets out to challenge some of the perceptions of the generic industry such as fluctuations in generic medicine prices and sustainability. In the paper, Pete shares generic medicine reimbursement prices insights gathered by Accord over the last 5 years. These insights show that despite some major events such as the Falsified Medicines Directive (FMD), Brexit and the pandemic, the market has remained consistent and resilient in the face of increasing odds.
Pete explains that not only are generics providing value for the NHS, but the introduction of biosimilars has meant that generic manufacturers are evolving in order to bring the next generation of medicines to more patients.
You can read more about how the lines between generic and biosimilar manufacturers are blurring with traditional ‘Big pharma companies’ and the benefit it brings to the NHS and patients in our White Paper ‘Innovation not Imitation’.
You can also read our first White Paper ‘UK Generic Medicine Price Flux? The real data behind the headlines’.
